Xenetic BiosciencesXBIO
Market Cap: $6.06M
About: Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
Employees: 4
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0.31% less ownership
Funds ownership: 1.27% [Q1] → 0.97% (-0.31%) [Q2]
16% less capital invested
Capital invested by funds: $73.8K [Q1] → $62K (-$11.7K) [Q2]
29% less funds holding
Funds holding: 7 [Q1] → 5 (-2) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Research analyst outlook
We haven’t received any recent analyst ratings for XBIO.